131374-93-1

Lobaplatin (D-19466), is a third-generation platinum-based antitumor drug developed by German ASTA Medica AG after cisplatin and carboplatin.

Lobaplatin is mainly used in the treatment of advanced breast cancer, small cell lung cancer and chronic myeloid leukemia.

Lobaplatin has a clear cytotoxic effect on a variety of animal and human tumor cell lines, which is equivalent to or better than the tumor suppressor effect of cisplatin, and overcomes the nephrotoxicity and digestive tract toxicity of cisplatin.